King completes Elan deal
Executive Summary
King completes acquisition of Elan's primary care business, including muscle relaxant Skelaxin and insomnia agent Sonata. King initially refused to complete the deal in light of Federal Trade Commission inquiry into Skelaxin "Orange Book" patent listings (1"The Pink Sheet" May 26, 2003, p. 14)...
You may also be interested in...
King/Elan Deal Proceeds; Skelaxin Royalties Will Offset Lower Purchase Price
King will pay Elan royalties on sales of the muscle relaxant Skelaxin under a restructured agreement for Elan's primary care business
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.